Plain-English translation of NCT06940791 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing whether a medication called can help prevent primary central nervous system lymphoma from returning after you've gone into remission following chemotherapy. Half of the participants will take daily, while the other half will take a placebo (a pill with no active medication). Researchers want to see if this medication can keep the lymphoma away longer than observation alone.
Brain lymphoma can come back even after successful chemotherapy treatment. This trial is exploring whether taking this medication for a longer period might prevent that recurrence and help patients stay healthy longer.
You likely qualify if…
You likely don't qualify if…
You will take either or a placebo as a daily pill and continue until your disease progresses or you experience unacceptable side effects. You'll visit the clinic every 4 weeks for check-ups, blood tests, and to receive your next month's supply of medication. The trial is double-blind, meaning neither you nor your doctor will know whether you're receiving the active medication or the placebo.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
Japan